Belantamab mafodotin-blmf is now indicated for adult patients with relapsed or refractory myeloma who have received at least 4 prior therapies.
Ryan Nolan, PharmD Candidate 2021
Advertisement
Articles by Ryan Nolan, PharmD Candidate 2021
On October 22, 2020, the FDA approved remdesivir (Veklury; Gilead) as the first treatment for coronavirus disease 2019 (COVID-19).
Advertisement
Latest Updated Articles
Belantamab mafodotin-blmf for Relapsed or Refractory Multiple MyelomaFebruary 12th 2021
Remdesivir in the Treatment of COVID-19January 14th 2021
Advertisement
Advertisement
Trending on Drug Topics
1
CDC Will Focus on BA.2.3 COVID-19 Variant for Upcoming Respiratory Season
2
Alabama Board of Medical Examiners Issues Warning of Non-FDA-Approved Peptides
3
Executive Order Calls for Realignment of Childhood Vaccines
4
Consonus Healthcare Named One of the First Pharmacies for Age-Friendly Pharmacy Recognition
5